NovoCure (纳斯达克代码：NVCR) 报告称季度每股亏损$(0.61)，未达到分析师共识预期的$(0.34)，差79.41%。 这比去年同期每股亏损$(0.45)下降了35.56%。公司报告季度销售额为1.6127亿美元，高于分析师共识预期的1.5781亿美元，增长2.19%。 这比去年同期1.3378亿美元的销售额增加了20.54%。

以上内容来自Benzinga Earnings专栏，原文如下：

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.34) by 79.41 percent. This is a 35.56 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $161.27 million which beat the analyst consensus estimate of $157.81 million by 2.19 percent. This is a 20.54 percent increase over sales of $133.78 million the same period last year.